Buckler Biomedical LLC

Our goal is to create resources for the advancement of clinical and basic sciences by pioneering methods in the instrumentation and information sciences that integrate imaging, clinical, and molecular data.

There is a large and growing body of knowledge at the cell level which feeds increasing utilization of in-silico methods in drug discovery and development. 
Likewise, there is a large and growing body of knowledge at the organism level which enables development of “smart devices” ranging from implantables to CAD
and CDSS.  However, there is comparatively little available technology to bridge these two bodies of knowledge.  Technology linking these scales materially advances the complementary goals of predictive, preventative, and personalized medicine.

Biologically informed models of increasing predictive power, trained by progressively sophisticated biomedical signal exploitation and in-vivo imaging algorithms, are of increasing significance in the development of novel drugs and therapeutic approaches.  Moreover, embedding such models in solutions for clinical care offer adaptive and personalized monitoring and control capabilities. 

Analytical processing of quantitative data, whether time-series or imaging, enables applications such as:

• Quantitative biomarkers, for development or intervention;
• Closed loop control for such applications as target controlled infusion (anesthesia) or cardiovascular assist devices;
• Novel tracer validation;
• Characterization of pathogenesis for disease signature discovery, such as angiogenesis or vulnerable plaque;
• Quantification of applications in receptor binding studies, absolute blood flow, and redox reactions using compartment modeling techniques.

Active research topics include:

• Scale- and noise-equivalent information content in biomedical signal exploitation,
• Representation of statistical confidence measures in time-series data alarm applications or in-vivo imaging studies.

As important as the specific hardware and software functional capabilities are, it is equally important that consideration of bias and variance be considered early in the design phase.  Likewise, pursuit of appropriate standards across stakeholders and compliance thereto by individual providers is key not only for society to benefit from developments but as well for manufacturers to realize the full return on their investments.  Central to these issues is the engagement with regulatory agencies for determination and utilization of appropriate regulatory pathways. 

Buckler Biomedical is pleased to be working with RSNA on a large scale initiative regarding the qualification and use of quantitative imaging, including participating in the leadership of the "Quantitative Imaging Biomarker Alliance" (QIBA).  Please refer to the RSNA web page devoted to these efforts for more information.